Literature DB >> 24391399

Antithrombin III Utilization in a Large Teaching Hospital.

Cristina M Salas, Marta A Miyares.   

Abstract

In a retrospective study to assess the use of antithrombin concentrates, the authors judged the plasma-derived product (Thrombate III) to be more cost-effective than the recombinant human form (ATryn) for patients with hereditary antithrombin deficiency.

Entities:  

Keywords:  ATryn; Thrombate III; antithrombin; venoocclusive disease

Year:  2013        PMID： 24391399      PMCID： PMC3875262     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  33 in total

Review 1.  Uses of antithrombin III concentrate in congenital and acquired deficiency states.

Authors:  S Z Bucur; J H Levy; G J Despotis; B D Spiess; C D Hillyer
Journal:  Transfusion       Date:  1998-05       Impact factor: 3.157

2.  Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.

Authors:  M Simon; T Hahn; L A Ford; B Anderson; D Swinnich; M R Baer; B Bambach; S H Bernstein; Z P Bernstein; M S Czuczman; J L Slack; M Wetzler; G Herzig; J Schriber; P L McCarthy
Journal:  Bone Marrow Transplant       Date:  2001-03       Impact factor: 5.483

3.  Single-dose application of antithrombin as a potential alternative anticoagulant during continuous renal replacement therapy in critically ill patients with advanced liver cirrhosis: a retrospective data analysis.

Authors:  Richard Brunner; Waltraud Leiss; Christian Madl; Wilfred Druml; Ulrike Holzinger
Journal:  Anesth Analg       Date:  2013-02-11       Impact factor: 5.108

Review 4.  Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.

Authors:  R S Schwartz; K A Bauer; R D Rosenberg; E J Kavanaugh; D C Davies; D A Bogdanoff
Journal:  Am J Med       Date:  1989-09-11       Impact factor: 4.965

5.  Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.

Authors:  J D Morris; R E Harris; R Hashmi; J E Sambrano; R A Gruppo; A T Becker; C L Morris
Journal:  Bone Marrow Transplant       Date:  1997-11       Impact factor: 5.483

6.  Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.

Authors:  Ursula Haussmann; Joachim Fischer; Stefan Eber; Franziska Scherer; Reinhard Seger; Tayfun Gungor
Journal:  Haematologica       Date:  2006-06       Impact factor: 9.941

7.  The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation.

Authors:  K Ohashi; J Tanabe; R Watanabe; T Tanaka; H Sakamaki; A Maruta; S Okamoto; N Aotsuka; K Saito; M Nishimura; H Oh; M Matsuzaki; S Takahashi; S Yonekura
Journal:  Am J Hematol       Date:  2000-05       Impact factor: 10.047

8.  A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.

Authors:  S H Park; M H Lee; H Lee; H S Kim; K Kim; W S Kim; C W Jung; Y H Im; S S Yoon; W K Kang; K Park; C H Park; S W Kim
Journal:  Bone Marrow Transplant       Date:  2002-01       Impact factor: 5.483

9.  Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.

Authors:  J H Essell; M T Schroeder; G S Harman; R Halvorson; V Lew; N Callander; M Snyder; S K Lewis; J P Allerton; J M Thompson
Journal:  Ann Intern Med       Date:  1998-06-15       Impact factor: 25.391

10.  Veno occlusive disease: update on clinical management.

Authors:  M Senzolo; G Germani; E Cholongitas; P Burra; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742
View more
  2 in total

1.  Comparison of Protective Effects of Recombinant Antithrombin Gamma and Plasma-Derived Antithrombin on Sepsis-Induced Disseminated Intravascular Coagulation and Multiple Organ Failure.

Authors:  Hiromitsu Kuroda; Yoshiki Masuda
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 2.  Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.

Authors:  Prajeeda M Nair; Matthew J Rendo; Kristin M Reddoch-Cardenas; Jason K Burris; Michael A Meledeo; Andrew P Cap
Journal:  Semin Hematol       Date:  2020-07-27       Impact factor: 3.851
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.